%PDF-1.4
%
133 0 obj
<>
endobj
135 0 obj
<>stream
2020-06-11T09:29:13-04:00
2020-07-06T04:09:13-07:00
2020-07-06T04:09:13-07:00
itext-paulo-155 (itextpdf.sf.net-lowagie.com)
application/pdf
ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials
uuid:11110352-1dd2-11b2-0a00-a608271dc500
uuid:11110356-1dd2-11b2-0a00-1e0000000000
endstream
endobj
128 0 obj
<>
endobj
1 0 obj
<>
endobj
136 0 obj
<>
endobj
137 0 obj
<>
endobj
138 0 obj
<>
endobj
12 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/ProcSet[/PDF/Text]>>/StructParents 11/Tabs/S/Type/Page>>
endobj
13 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/ProcSet[/PDF/Text]>>/StructParents 12/Tabs/S/Type/Page>>
endobj
14 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/Font<>/ProcSet[/PDF/Text]>>/StructParents 13/Tabs/S/Type/Page>>
endobj
15 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/ProcSet[/PDF/Text]>>/StructParents 14/Tabs/S/Type/Page>>
endobj
16 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/Font<>/ProcSet[/PDF/Text]>>/StructParents 15/Tabs/S/Type/Page>>
endobj
17 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/ProcSet[/PDF/Text]>>/StructParents 16/Tabs/S/Type/Page>>
endobj
18 0 obj
<>/MediaBox[0 0 595.02 841.02]/Parent 138 0 R/Resources<>/ProcSet[/PDF/Text]>>/StructParents 17/Tabs/S/Type/Page>>
endobj
19 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/Type/Page>>
endobj
139 0 obj
<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
163 0 obj
[169 0 R 170 0 R 171 0 R 172 0 R 173 0 R 174 0 R]
endobj
164 0 obj
<>stream
q
539.3594055 0 0 83.3014526 27.8202972 709.6985474 cm
/Im0 Do
Q
BT
/T1_0 1 Tf
10 0 0 10 105.56992 575.99979 Tm
( Published OnlineFirst June 16, 2020.)Tj
/T1_1 1 Tf
-7.55699 0 Td
(Clin Cancer Res\240)Tj
/T1_0 1 Tf
0 1 TD
(\240 )Tj
0 1.00001 TD
(Nicholas C. Turner, Claire Swift, Lucy S Kilburn, et al. )Tj
/T1_2 1 Tf
0 1 TD
(\240 )Tj
/T1_3 1 Tf
18 0 0 18 30 615.99991 Tm
(EFECT trials)Tj
T*
(cancer: A combined analysis of the phase III SoFEA and)Tj
T*
(exemestane in advanced hormone receptor positive breast )Tj
0 1.00001 TD
(ESR1 mutations and overall survival on fulvestrant versus)Tj
ET
30 455 535 101 re
0 0 m
S
BT
/T1_0 1 Tf
11 0 0 11 120.94202 528.99997 Tm
(\240 )Tj
/T1_3 1 Tf
-7.55696 1 Td
(Updated version)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 141 520.99994 Tm
(\240 )Tj
/T1_0 1 Tf
16.73098 1 Td
( )Tj
0 0 1 rg
-15.11897 0 Td
(10.1158/1078-0432.CCR-20-0224)Tj
0 g
-1.61201 0 Td
(doi:)Tj
T*
(Access the most recent version of this article at:)Tj
ET
BT
/T1_0 1 Tf
11 0 0 11 120.94202 487.99994 Tm
(\240 )Tj
/T1_3 1 Tf
-3.50099 1 Td
(Material)Tj
-3.44499 1.00001 Td
(Supplementary)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 141 490.99994 Tm
(\240 )Tj
/T1_0 1 Tf
41.12993 1 Td
( )Tj
0 0 1 rg
-41.12993 0 Td
(http://clincancerres.aacrjournals.org/content/suppl/2020/06/16/1078-0432\
.CCR-20-0224.DC1)Tj
0 g
T*
(Access the most recent supplemental material at:)Tj
ET
BT
/T1_0 1 Tf
11 0 0 11 120.94202 454.99994 Tm
(\240 )Tj
/T1_3 1 Tf
-5.05597 1 Td
(Manuscript)Tj
2.05699 1.00001 Td
(Author)Tj
ET
BT
/T1_0 1 Tf
10 0 0 10 141 467.99997 Tm
(been edited. )Tj
0 1 TD
(Author manuscripts have been peer reviewed and accepted for publication \
but have not yet)Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 30 434.99997 Tm
(\240 )Tj
T*
(\240 )Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 30 414.99997 Tm
(\240 )Tj
T*
(\240 )Tj
ET
BT
/T1_2 1 Tf
10 0 0 10 30 394.99997 Tm
(\240 )Tj
T*
(\240 )Tj
ET
30 280 535 115 re
0 0 m
S
BT
/T1_0 1 Tf
11 0 0 11 120.94202 362.99997 Tm
(\240 )Tj
/T1_3 1 Tf
-5.66901 1 Td
(E-mail alerts)Tj
ET
BT
/T1_0 1 Tf
10 0 0 10 295.49973 375 Tm
( related to this article or journal.)Tj
0 0 1 rg
-15.44997 0 Td
(Sign up to receive free email-alerts)Tj
ET
BT
0 g
/T1_0 1 Tf
11 0 0 11 120.94202 329.99994 Tm
(\240 )Tj
/T1_3 1 Tf
-6.38997 1 Td
(Subscriptions)Tj
0.556 1.00001 Td
(Reprints and )Tj
ET
BT
/T1_0 1 Tf
10 0 0 10 141 332.99994 Tm
(\240 )Tj
13.46497 1 Td
(.)Tj
0 0 1 rg
-6.85098 0 Td
(pubs@aacr.org)Tj
0 g
-6.61399 0 Td
(Department at)Tj
0 1.00001 TD
(To order reprints of this article or to subscribe to the journal, contac\
t the AACR Publications)Tj
ET
BT
/T1_0 1 Tf
11 0 0 11 120.94202 307.99997 Tm
(\240 )Tj
/T1_3 1 Tf
-5.66901 1 Td
(Permissions)Tj
ET
BT
/T1_0 1 Tf
10 0 0 10 141 279.99988 Tm
(\240 )Tj
0 1 TD
(Rightslink site. )Tj
0 1.00001 TD
(Click on "Request Permissions" which will take you to the Copyright Clea\
rance Center's \(CCC\))Tj
38.62893 1 Td
(.)Tj
0 0 1 rg
-38.62893 0 Td
(http://clincancerres.aacrjournals.org/content/early/2020/06/16/1078-0432\
.CCR-20-0224)Tj
0 g
0 1 TD
(To request permission to re-use all or part of this article, use this li\
nk)Tj
ET
BT
/T1_0 1 Tf
9 0 0 9 274.74251 1.99997 Tm
(Research. )Tj
0.57448 1 Td
(on July 6, 2020. \251 2020 American Association for Cancer)Tj
0 0 1 rg
-13.61496 0 Td
(clincancerres.aacrjournals.org )Tj
0 g
-8.11398 0 Td
(Downloaded from )Tj
ET
BT
/T1_0 1 Tf
9 0 0 9 88.13573 818.99997 Tm
(Author manuscripts have been peer reviewed and accepted for publication \
but have not yet been edited. )Tj
1.0855 1 Td
(Author Manuscript Published OnlineFirst on June 16, 2020; DOI: 10.1158/1\
078-0432.CCR-20-0224 )Tj
ET
endstream
endobj
168 0 obj
<>/Filter/FlateDecode/Height 238/Length 73913/Name/X/Subtype/Image/Type/XObject/Width 1541>>stream
HϏn`'G6R0"#AKH"9\C| \?9-5= w#b"`ͼJ13;uKUoOu{^E +CD. K @Dd GD. K @Dd GD. K @Dd GD. K @Dd GD. K @Dd GD. K @Dd GD. K @Dd GD. K @Dd i꺖lƽeYڽ=
!Y2u]QEIeUQ:h\yq]&;qjm#qb^նmUUI-Vmi݃s}
էIiԮ{[R&LڝX;
;A;lDzog^ ilf $L2쪇͓ؿy$N&oar@1i|X$ݾwN9߄ͷ11&ldD ǩ}ƏVovT:np9i_ABM2$)4G&ʲL^UMupzXz~k˶
U\:p+aw!s+sa,ڙvm۪M5fIYO|IuUl1-&(|>Y&J%n0n/2%Ǻlnag^84|sb4 />]TI~~km۪lh4wY#nI:7eY~-İV?ߴML66C-睔Mj\